Bachelor of Biotechnology, graduated at the Federal University of Paraíba. I have experience in Biotechnology, with emphasis in cellular and molecular Biology. In my undergraduate studies I conducted some research projects to analyse the cytotoxicity effect of natural and synthetic bioactive compounds in cancer and non-cancer cells and its characteristics of cell death (2014 2017) in the Cellular and Molecular Biotechnology Laboratory from the Department of Biotechnology at the Federal University of Paraíba, with the Professor PhD Demetrius Antonio Machado de Araujo as my advisor. Currently, in the master's degree program of Medical Sciences (CAPES 6) of the Department of Clinical Medicine at the Faculty of Medicine of the University of São Paulo, FMUSP, developing research projects in the acute leukemia area, with emphasis on in vitro and in vivo models of acute myeloid leukemia in the Laboratory of Experimental Hematology, under the supervision of Professor PhD Eduardo Magalhães Rego. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Acute Myeloid Leukemia (AML) is a genetically, epigenetically, and clinically heterogeneous group of clonal Bone Marrow (BM) diseases. Since its treatment has not undergone major changes in the last decades, long-term disease outcomes have not shown significant improvement over the years. Furthermore, the therapies currently used have high systemic toxicity, thus making it necessary to st…
Among myeloid neoplasms, acute myeloid leukemia (AML) is a heterogeneous group of clonal bone marrow diseases that affect hematopoietic progenitors making them unable to differentiate terminally and to respond to natural regulators of cell death and proliferation. The bone marrow microenvironment acts as an important factor in the development, progression, maintenance and evolution of AML…
Acute myeloid leukemia (AML) is an aggressive disease with dismal clinical outcome primarily affecting older individuals, frequently unsuitable for intensive chemotherapy. Current, non-intensive chemotherapeutic options, include hypomethylating agents and low-dose of cytarabine, while the differentiation agent all trans retinoic acid (ATRA) has shown success exclusively in acute promyeloc…
| 1 / 1 | Ongoing scholarships in Brazil |
| 1 / 1 | Completed scholarships in Brazil |
| 1 / 1 | Completed scholarships abroad |
| 3 / 3 | All Scholarships |
| Associated processes | |
CV Lattes
ORCID